HR 7877 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
Summary
The Shane DiGiovanna Act requires the Department of Health and Human Services to conduct a two-year nationwide demonstration program testing mandatory Medicaid coverage of wound care treatment for epidermolysis bullosa, a rare genetic skin disorder. The program would cover over-the-counter antihistamines, pain relievers, anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, and wound care supplies such as dressings and gauze for eligible Medicaid beneficiaries. The demonstration would begin within one year of the law's enactment. Within one year after the program ends, the Department must submit a report to Congress evaluating the program's effects on Medicaid expenditures, analyzing health outcomes for participants, and providing recommendations on preventing hospitalizations related to epidermolysis bullosa.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Landsman, Greg [D-OH-1] (D-OH)
5 cosponsors
Actions (3)
- Mar 17, 2026 Sponsor introductory remarks on measure. (CR H2535)
- Mar 9, 2026 Referred to the House Committee on Energy and Commerce. · house
- Mar 9, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
March 9, 2026
Mr. Landsman introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Shane DiGiovanna Act”.
SEC. 2. DEMONSTRATION PROGRAM TO TEST MANDATORY COVERAGE OF TREATMENT FOR WOUND CARE FOR EPIDERMOLYSIS BULLOSA UNDER THE MEDICAID PROGRAM.
(a) In General.—Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the “Secretary”) shall conduct a 2- year demonstration program under which items and services specified in subsection (b) furnished for the treatment of epidermolysis bullosa are required to be included as medical assistance under a State plan (or waiver of such plan) under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) for individuals described in section 1902(a)(10)(A)(i) of such Act (42 U.S.C. 1396a(a)(10)(A)(i)).
(b) Specified Items and Services.—For purposes of subsection (a), the items and services specified in this subsection are over-the- counter antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, and necessary wound care supplies, including wound care dressings (inclusive of primary and secondary dressings), gauze, and bandage retainers.
(c) Scope of Demonstration.—The Secretary shall conduct the demonstration program described in subsection (a) on a nationwide basis.
(d) Study.—Not later than 1 year after the end of the demonstration program described in subsection (a), the Secretary shall submit to Congress a report on such program. Such report shall include the following:
(1) An evaluation of the effect of such program on expenditures for treatment of individuals with epidermolysis bullosa under the Medicaid program (taking into account any such treatment avoided due to such program).
(2) An analysis of health outcomes for such individuals compared to such outcomes before such program.
(3) Any recommendations relating to how to prevent hospitalizations relating to epidermolysis bullosa. <all>
Comments